Category

NASDAQ

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering NASDAQ

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an aggregate of 1,800,876 shares of…
bubmag
May 12, 2023
Sunworks To Postpone First Quarter 2023 Results Conference Call and Webcast NASDAQ

Sunworks To Postpone First Quarter 2023 Results Conference Call and Webcast

PROVO, UT / ACCESSWIRE / May 12, 2023 / Sunworks, Inc. (Nasdaq:SUNW, "Sunworks" or the "Company"), a leading provider of solar power and battery storage solutions for residential, agriculture, commercial, industrial, and public works markets, today announced that it intends to postpone the issuance of its first quarter 2023 results…
bubmag
May 12, 2023
Generation Income Properties Announces First Quarter 2023 Financial and Operating Results NASDAQ

Generation Income Properties Announces First Quarter 2023 Financial and Operating Results

TAMPA, FL / ACCESSWIRE / May 12, 2023 / Generation Income Properties, Inc. (NASDAQ:GIPR) ("GIPR" or the "Company") today announced its financial and operating results for the three-month period ended March 31, 2023. Highlights (For the 3 months ended March 31, 2023) Generated net loss attributable to GIPR of ($1.3…
bubmag
May 12, 2023
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress NASDAQ

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozole Median duration of response (DOR) was 46.9 months MINNEAPOLIS, MN / ACCESSWIRE / May 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology…
bubmag
May 12, 2023